CSNK1D and cancer: This study provides a basis for the development and use of selective CSNK1D inhibitors to abrogate HH—GLI signaling in SMOi-sensitive and SMOi-resistant settings, which is an important step towards the development of novel oncology drugs targeting GLI transcription factors to eliminate highly malignant cancer stem cells.